ArticleVirchows Archiv : an international journal of pathology2025
Comprehensive morphological, immunohistochemical, and molecular characterization of congenital pulmonary airway malformation (CPAM).
Article in Virchows Archiv : an international journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Congenital pulmonary airway malformation mimicking lung cancer in adults: a pitfall in oncologic diagnosis.Quantitative imaging in medicine and surgery · 2026Article
- An extremely rare case of congenital pulmonary airway malformation (CPAM) and atypical adenomatous hyperplasia (AAH) with EGFR mutation in a five-year-old girl.BMC pediatrics · 2026Article
- Prenatal trio-based whole exome sequencing in fetuses with congenital pulmonary airway malformation.Translational pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Congenital pulmonary airway malformation (CPAM) is among the most common congenital lung disorders. Possible findings are foci of mucinous cell clusters (MCCs), harboring KRAS mutations. Studies combining morphology, immunohistochemistry (IHC), and molecular data are scarce. A total of. 46 CPAM lesions were assessed by conventional histomorphology. IHC was performed to analyze lung-specific markers, transcription factors, and epithelial markers reflecting the structural composition of the bronchial tree and alveolar system. Next-generation sequencing (NGS) was conducted to identify mutations and fusions. CPAM type 1 was found in 50%, type 2 in 22%, and type 3 in 6%. A mixed pattern of types 1 and 2 was observed in 22%. The epithelial lining was strongly positive for CK7 and TTF-1 in all samples. Expression for Napsin A, Surfactant A, p40, CK5/6, and CK20 varied within and between subtypes. P40 and CK5/6 were more enriched in type 1 compared to type 2. MCCs occurred in 17%. Mutations were found in 24% (9 × KRAS; 2 × FGFR2). Besides classical KRAS mutations (G12D, G12V), two cases showed a double-mutation pattern (G12D/G12V; G12D/TP53). In all MCC cases, the same mutation with comparable allele frequencies was found in mucinous and non-mucinous areas. No fusions were detected. The presence of mixed-type patterns supports the hypothesis that CPAM represents a continuum of developmental disturbances occurring at various stages of lung branching morphogenesis. This is further corroborated by the divergent protein expression patterns. Our study confirms recent findings that the same KRAS mutations occur in mucinous and non-mucinous areas. The identification of additional mutations, including potential co-mutations, underscores the need for further investigation into molecularly defined CPAM subtypes.
Indexed as
Identifiers
40473982What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.